An Extension Study to Evaluate the Long-term Outcomes of Subjects Who Received Treatment for Retinopathy of Prematurity in Study 20090
Latest Information Update: 05 Jun 2025
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinopathy of prematurity
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms FIREFLEYE next
- Sponsors Bayer
Most Recent Events
- 04 Apr 2024 Planned End Date changed from 3 Jul 2025 to 1 Oct 2025.
- 04 Apr 2024 Planned primary completion date changed from 3 Jul 2025 to 1 Oct 2025.
- 16 Jul 2023 This trial has been discontinued in Netherlands, according to European Clinical Trials Database.